Table 1. Characterization of tumorigenicity and effects of sh-CBX5 RNAi in lung CD133+-TSLCs from 7 non-small cell lung cancer (NSCLC) patient.
| Number of cells injected (Number of animals having tumor/Total of 3 animals in each experiment) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| NSCLC Case | Age/Sex/Type/Stage | CD133+ (%) | Spheres Formation | CD133+ | CD133+ sh-RNA vector | CD133+ sh-CBX5 | CD133+ IR-4 Gy | CD133+ sh-CBX5 & IR 4 Gy | CD133− |
| 1 | 82/M/AD/IIIa | 7.1 | Yes | 1,000 (3/3) | 1,000 (2/3) | 1,000 (0/3) | 1,000 (2/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (3/3) | 3,000 (3/3) | 3,000 (0/3) | 3,000 (2/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (3/3) | 10,000 (3/3) | 10,000 (1/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (0/3) | ||||
| 2 | 59/F/AD/IIb | 4.8 | Yes | 1,000 (2/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (1/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (2/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (3/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (2/3) | 10,000 (1/3) | 10,000 (0/3) | ||||
| 3 | 63/F/AD/IIb | 3.6 | Yes | 1,000 (1/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (1/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (2/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (2/3) | 10,000 (2/3) | 10,000 (1/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (0/3) | ||||
| 4 | 70/M/SC/IIb | 11.2 | Yes | 1,000 (3/3) | 1,000 (3/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (3/3) | 3,000 (3/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (3/3) | 10,000 (3/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (0/3) | ||||
| 5 | 75/M/AD/IIa | 3.9 | Yes | 1,000 (1/3) | 1,000 (2/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (2/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (2/3) | 10,000 (2/3) | 10,000 (1/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (0/3) | ||||
| 6 | 67/M/AD/IIb | 15.5 | Yes | 1,000 (3/3) | 1,000 (3/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (3/3) | 3,000 (2/3) | 3,000 (1/3) | 3,000 (3/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (3/3) | 10,000 (3/3) | 10,000 (2/3) | 10,000 (3/3) | 10,000 (1/3) | 10,000 (1/3) | ||||
| 7 | 68/M/SC/Ib | 2.3 | Yes | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) | 1,000 (0/3) |
| 3,000 (1/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (1/3) | 3,000 (0/3) | 3,000 (0/3) | ||||
| 10,000 (2/3) | 10,000 (1/3) | 10,000 (1/3) | 10,000 (2/3) | 10,000 (0/3) | 10,000 (0/3) | ||||
NSCLC: non-small cell lung carcinoma. Tumor types- AD: lung adenocarcinoma; SC: lung squamous cell carcinoma. Tumor grade/stage: TMN staging.
sh-CBX5 & IR 4 Gy: combined sh-CBX5 RNAi with IR (4Gy) treatment. Cells were transplanted into NOD-SCID mice through the tail vein.
After 8 weeks of transplantation, the tumorigenic ability of tumor-bearing NOD-SCID mice was measured by histological survey in the whole lung.